U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07707674) titled 'Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer' on July 06.
Brief Summary: A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects with Metastatic Pancreatic Cancer
Study Start Date: July 30
Study Type: INTERVENTIONAL
Condition:
Metastatic Pancreatic Cancer
Intervention:
DRUG: XNW28012
XNW28012 is an antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) targeting Tissue Factor (TF) and a topoi...